What happened
Neopharm filed provisional (unaudited) separate results for Q1 2026: revenue of US$24.9M (+14.6% year on year), operating profit of US$5.98M (+11.9% year on year) and net income of US$5.93M (+20.9% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$24.9M |
|---|---|
| Revenue vs a year earlier | +14.6% |
| Operating profit | US$5.98M |
| Net income | US$5.93M |
| Period | Q1 2026 (separate) |
| Filed | 2026-05-08, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260508900861 → open original filing |
Source: DART. Information only, not investment advice.